Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 6 Japan Drug Makers Net 20% Growth in China Biz Despite COVID-19 Woes
June 1, 2020
-
REGULATORY Oral Semaglutide Clears MHLW Panel, Now in Line for June Approval
June 1, 2020
-
ACADEMIA Japan to Join NIH’s Remdesivir-Baricitinib Combo Trial for COVID-19
June 1, 2020
-
BUSINESS Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
May 29, 2020
-
ACADEMIA Nagasaki Univ. to Launch Clinical Trial for Nelfinavir for COVID-19
May 28, 2020
-
BUSINESS Drug Makers Exploring “New Normal” in Post-COVID-19; Takeda Plans Major Changes
May 28, 2020
-
BUSINESS Japan SGLT2 Inhibitor Market Hits 100 Billion Yen after Weak Start: Jiho Estimate
May 27, 2020
-
REGULATORY Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
-
ACADEMIA Discontinued HIV Med Nelfinavir Hits Limelight as Potential COVID-19 Treatment
May 26, 2020
-
REGULATORY MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
-
BUSINESS GSK Japan Looking to Develop Otilimab for COVID-19; President Stresses Efforts on Vaccines, Disease Management Too
May 22, 2020
-
ACADEMIA Avigan Interim Analysis Not Intended to Determine Efficacy, Research Sponsor Says on Reports
May 21, 2020
-
REGULATORY MHLW Adds Veklury in Updated COVID-19 Treatment Guide
May 20, 2020
-
BUSINESS Nichi-Iko Launches Another Recall, Now Pulling 8 More APIs/9 Products
May 19, 2020
-
REGULATORY Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
-
BUSINESS Many Drug Makers Continue Work-from-Home, Voluntary Visit Bans after Govt Partially Lifts COVID-19 Emergency
May 18, 2020
-
BUSINESS Takeda Revving Up Efforts to Retool Japan Sales System as It Prepares for “New Normal” Post COVID-19
May 18, 2020
-
REGULATORY Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
-
REGULATORY Japan Poised to Quickly Approve Futhan, Actemra, Ivermectin for COVID-19 If Effective: Abe
May 15, 2020
-
REGULATORY Chuikyo Members Frown on Zolgensma’s Sakigake Premium; Topic Up for 2022 Pricing Debate
May 14, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…